The Pathogenicity and Synergistic Action of Th1 and Th17 Cells in Inflammatory Bowel Diseases

Inflammatory bowel diseases (IBDs), including ulcerative colitis and Crohn's disease, are characterized by chronic idiopathic inflammation of gastrointestinal tract. Although the pathogenesis of IBD remains unknown, intestinal immune dysfunction has been considered as the core pathogenesis. In the intestinal immune system, T helper 1 (Th1) and Th17 cells are indispensable for intestine homeostasis via preventing pathogenic bacteria invasion, regulating metabolism and functions of intestinal epithelial cells (IECs), and promoting IEC self-renewal. However, during the development of IBD, Th1 and Th17 cells acquire the pathogenicity and change from the maintainer of intestinal homeostasis to the destroyer of intestinal mucosa. Because of coexpressing interferon-gamma and interleukin-17A, Th17 cells with pathogenicity are named as pathogenic Th17 cells. In disease states, Th1 cells impair IEC programs by inducing IEC apoptosis, recruiting immune cells, promoting adhesion molecules expression of IECs, and differentiating to epithelial cell adhesion molecule-specific interferon gamma-positive Th1 cells. Pathogenic Th17 cells induce IEC injury by triggering IBD susceptibility genes expression of IECs and specifically killing IECs. In addition, Th1 and pathogenic Th17 cells could cooperate to induce colitis. The evidences from IBD patients and animal models demonstrate that synergistic action of Th1 and pathogenic Th17 cells occurs in the diseases development and aggravates the mucosal inflammation. In this review, we focused on Th1 and Th17 cell programs in homeostasis and intestine inflammation and specifically discussed the impact of Th1 and Th17 cell pathogenicity and their synergistic action on the onset and the development of IBD. We hoped to provide some clues for treating IBD. Lay Summary Although treatment methods have been comprehensively optimized, the death risk of inflammatory bowel disease (IBD) patients is higher than that of healthy control subjects and still gradually increasing. Even so, the pathogenesis of IBD remains poorly understood. A better understanding of the roles of T helper 1 and pathogenic T helper 17 cells in the pathogenesis of IBD may provide some promising clues for treating IBD.

Automated summary

Inflammatory bowel diseases (IBDs), including ulcerative colitis and Crohn's disease, are characterized by chronic idiopathic inflammation of the gastrointestinal tract. The pathogenesis of IBD is largely unknown, but it is believed that intestinal immune dysfunction plays a key role. Th1 and Th17 cells, which are essential for maintaining intestinal homeostasis, become pathogenic during the development of IBD and contribute to the inflammation and damage of the intestinal mucosa. Th1 cells impair intestinal epithelial cell function, while pathogenic Th17 cells induce injury and cell death. The synergistic action of Th1 and pathogenic Th17 cells exacerbates mucosal inflammation in IBD.